What is HIND's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for HIND?

P/E (TTM) is n/a and 52-week range is $1.75 to $6.56 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s HIND figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for HIND?

The company profile lists revenue (TTM) near $130K, net income (TTM) near -$1.13B, EPS (TTM) near -$3.51 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Vyome Holdings Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Clemente, California, US, 7M shares outstanding, ISIN US92943X1046 when available from company profile and filing metadata.

Vyome Holdings Inc

$HIND

Health Care · Pharmaceuticals

IR Run Scenarios

Browse other companiesFree AI scores and summaries for more stocks

Vyome Holdings Inc

$HIND

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Vyome Holdings, Inc. engages in the development of immuno-inflammatory assets. The company is headquartered in San Clemente, California and currently employs 9 full-time employees. The company went IPO on 2016-10-06. The firm is focused on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. Its clinical program VT1953 Gel is focused on cancer patients who are suffering from malignant fungating wounds (MFW). Its preclinical development program, VT1908, is a non-steroidal eye drop, which is focused on Uveitis. Its other business unit is focused on offering artificial intelligence (AI)-driven healthcare solutions across mental health and inflammation care, digital therapeutics and psychoneuroimmunology.

Employees

9

Website

vyometx.com

IPO

2016-10-06

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US92943X1046

Headquarters

San Clemente, California, US

Shares outstanding

7M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

3.02%

Browse other companiesFree AI scores and summaries for more stocks

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Vyome Holdings, Inc. engages in the development of immuno-inflammatory assets. The company is headquartered in San Clemente, California and currently employs 9 full-time employees. The company went IPO on 2016-10-06. The firm is focused on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. Its clinical program VT1953 Gel is focused on cancer patients who are suffering from malignant fungating wounds (MFW). Its preclinical development program, VT1908, is a non-steroidal eye drop, which is focused on Uveitis. Its other business unit is focused on offering artificial intelligence (AI)-driven healthcare solutions across mental health and inflammation care, digital therapeutics and psychoneuroimmunology.

Employees

9

Website

vyometx.com

IPO

2016-10-06

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)